| Literature DB >> 32758226 |
Ashley W Blom1,2, Linda P Hunt1, Gulraj S Matharu3, Michael R Reed4, Michael R Whitehouse1,2.
Abstract
BACKGROUND: Total hip replacement (THR) is clinically and cost-effective. The surgical approach employed influences the outcome; however, there is little generalisable and robust evidence to guide practice.Entities:
Keywords: Hip replacement; Mortality; Outcomes; Revisions surgery; Surgical approach
Mesh:
Year: 2020 PMID: 32758226 PMCID: PMC7409663 DOI: 10.1186/s12916-020-01672-0
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Study selection criteria. Abbreviations: OA = osteoarthritis; MoM = metal-on-metal
Numbers in the approach groups with demographic information
| 394,735 (54.5) | 39.2% | 70 (62–76) | 3.5% | 15.0% | 70.1% | 14.5% | 0.4% | 32.3% | 39.8% | 24.5% | 3.4% | ||
| 22,663 (3.1) | 38.6% | 69 (62–76) | 2.8% | 20.4% | 70.0% | 9.2% | 0.3% | 13.4% | 72.9% | 10.8% | 3.0% | ||
| 260,415 (36.0) | 38.2% | 71 (64–77) | 2.6% | 14.0% | 70.0% | 15.9% | 0.6% | 46.0% | 36.6% | 15.3% | 2.1% | ||
| 9,101 (1.3) | 36.6% | 71 (64–78) | 2.4% | 19.3% | 68.1% | 12.3% | 0.3% | 33.9% | 51.8% | 12.9% | 1.4% | ||
| 26,582 (3.7) | 38.1% | 70 (63–77) | 3.1% | 13.4% | 71.5% | 14.7% | 0.4% | 32.6% | 43.6% | 22.0% | 1.8% | ||
| 3,830 (0.5) | 41.0% | 69 (61–75) | 3.1% | 18.7% | 66.7% | 14.3% | 0.3% | 7.0% | 83.7% | 8.9% | 0.5% | ||
| 6,578 (0.9) | 39.7% | 69 (62–76) | 5.2% | 15.6% | 69.0% | 15.0% | 0.3% | 85.8% | 8.1% | 5.0% | 1.1% | ||
| 394,735 (54.5) | 394,671 | 25.5% | 262,876 | 27.9% | 0.8% | 39.5% | 31.8% | ||||||
| 22,663 (3.1) | 22,662 | 36.8% | 15,371 | 35.4% | 1.1% | 40.3% | 23.2% | ||||||
| 260,415 (36.0) | 260,376 | 14.0% | 142,430 | 27.1% | 0.8% | 39.7% | 32.4% | ||||||
| 9,101 (1.3) | 9,097 | 12.1% | 4,175 | 32.1% | 1.1% | 40.6% | 26.2% | ||||||
| 26,582 (3.7) | 26,579 | 22.0% | 15,047 | 28.0% | 0.8% | 40.0% | 31.2% | ||||||
| 3,830 (0.5) | 3,829 | 41.0% | 1,952 | 30.4% | 1.0% | 44.5% | 24.1% | ||||||
| 6,578 (0.9) | 6,578 | 4.1% | 1,894 | 31.1% | 1.3% | 40.0% | 27.6% | ||||||
Lat/Ant-Lat/Hard lateral/anterolateral/Hardinge, Ant/Other anterior/other, IQR interquartile range, OA osteoarthritis, ASA American Society of Anesthesiologists Physical Status, BMI body mass index
*Age regarded as missing for 157 as the NHS number was not validated
Fig. 2Cumulative percentage revised (Kaplan-Meier) up to 12 years for the 7 surgical approach groups
Regression models to compare approach groups for revision risk (n = 723,747 with complete information)
| (i) Stratified Cox proportional hazards regression models, with stratification by age/sex/risk groups | ||||
| 1 [referent] | 1 [referent] | 1 [referent] | ||
| 0.99 [0.89–1.10] | 0.92 [0.83–1.02] | 0.89 [0.77–1.02] | ||
| 1.05 [1.01–1.09] | 1.07 [1.03–1.11] | 1.12 [1.06–1.17] | ||
| 1.31 [1.16–1.50] | 1.28 [1.13–1.46] | 1.02 [0.80–1.30] | ||
| 1.04 [0.95–1.14] | 1.03 [0.94–1.13] | 1.01 [0.88–1.15] | ||
| 1.67 [1.36–2.05] | 1.48 [1.21–1.82] | 1.03 [0.71–1.51] | ||
| 1.22 [1.07–1.40] | 1.40 [1.22–1.60] | 1.48 [1.14–1.91] | ||
| (ii) FPM models, with adjustment for time-varying effects of age, sex, risk group | ||||
| 0 [Referent] | 0 [Referent] | |||
| −0.006 [−0.109–0.096] | −0.081 [−0.183–0.022] | |||
| 0.056 [0.019–0.093] | 0.069 [0.031–0.106] | |||
| 0.282 [0.154–0.411] | 0.264 [0.135–0.392] | |||
| 0.031 [−0.063–0.126] | 0.019 [−0.075–0.114] | |||
| 0.516 [0.311–0.721] | 0.380 [0.174–0.585] | |||
| 0.213 [0.075–0.350] | 0.309 [0.170–0.448] | |||
Lat/Ant-Lat/Hard lateral/anterolateral/Hardinge, Ant/Other anterior/other, ASA American Society of Anesthesiologists Physical Status, BMI body mass index, CI confidence interval
Fig. 3Cumulative mortality up to 90 days (Kaplan-Meier) for the 7 surgical approach groups
Cox ‘proportional hazards’ regression model to compare 90-day mortality between the 7 approach subgroups
| 394,655 | 1 [referent] | 1 [referent] | 1 [referent] | ||
| 22,655 | 0.80 [0.62–1.04] | 0.88 [0.68–1.14] | 0.90 [0.69–1.17] | ||
| 260,353 | 1.38 [1.27–1.49] P < 0.001 | 1.14 [1.05–1.24] P = 0.002 | 1.14 [1.05–1.23] P = 0.002 | ||
| 9099 | 1.21 [0.87–1.69] | 1.02 [0.73–1.43] | 1.03 [0.74–1.44] | ||
| 26,578 | 1.03 [0.83–1.28] | 0.96 [0.77–1.19] | 0.96 [0.77–1.19] | ||
| 3829 | 0.80 [0.43–1.50] | 0.88 [0.47–1.65] | 0.91 [0.49–1.71] | ||
| 6578 | 1.49 [1.05–2.11] P = 0.026 | 1.19 [0.83–1.69] | 1.16 [0.81–1.65] | ||
| 1 [referent] | 1 [referent] | 1 [referent] | |||
| 0.91 [0.70–1.18] | 0.93 [0.68–1.27] | 0.87 [0.57–1.34] | |||
| 1.16 [1.06–1.26] P = 0.001 | 1.11 [1.01–1.21] P = 0.027 | 1.15 [1.01–1.30] P = 0.029 | |||
| 0.91 [0.63–1.31] | 0.87 [0.58–1.31] | 0.80 [0.41–1.55] | |||
| 0.96 [0.78–1.20] | 0.94 [0.75–1.19] | 0.89 [0.63–1.26] | |||
| 0.92 [0.49–1.71] | 1.23 [0.61–2.47] | 1.01 [0.32–3.15] | |||
| 1.16 [0.81–1.67] | 1.12 [0.75–1.68] | 1.12 [0.52–2.41] | |||
Lat/Ant-Lat/Hard lateral/anterolateral/Hardinge, Ant/Other anterior/other, ASA American Society of Anesthesiologists Physical Status, BMI body mass index, CI confidence interval
Cox ‘proportional hazards’ regression model to compare 90-day mortality between the 7 approach subgroups. Models from Table 3 were also adjusted for Charlson comorbidity subgroups, which were based on HES inpatient admissions within 5 years prior to date of primary THR operation
| 1 [referent] | 1 [referent] | 1 [referent] | ||
| 0.94 [0.69–1.28] | 0.94 [0.69–1.28] | 0.86 [0.56–1.33] | ||
| 1.13 [1.04–1.24] P = 0.007 | 1.12 [1.02–1.23] P = 0.013 | 1.16 [1.02–1.31] P = 0.022 | ||
| 0.89 [0.59–1.34] | 0.88 [0.59–1.33] | 0.81 [0.42–1.57] | ||
| 0.96 [0.76–1.21] | 0.96 [0.76–1.21] | 0.90 [0.64–1.27] | ||
| 1.29 [0.64–2.59] | 1.32 [0.66–2.65] | 1.10 [0.35–3.42] | ||
| 1.15 [0.77–1.73] | 1.15 [0.77–1.71] | 1.16 [0.54–2.50] | ||
Lat/Ant-Lat/Hard lateral/anterolateral/Hardinge, Ant/Other anterior/other, ASA American Society of Anesthesiologists Physical Status, BMI body mass index, CI confidence interval
*There were no 90-day deaths for human immunodeficiency virus so this was not included in the analysis